{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:20:57Z","timestamp":1788805257001,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Fixed drug eruption (FDE) is a non-immediate, CD8+ T cell\u2013mediated hypersensitivity reaction characterized by well-demarcated erythematous\u2013violaceous plaques that recur at the same site after re-exposure to the causative drug. Although NSAIDs and antibiotics are the most common triggers, various other medications may induce FDE, and genetic susceptibility has been linked to specific HLA alleles. Methods: We conducted a clinical evaluation supported by patch testing, oral drug provocation, and assessment of therapeutic alternatives to identify the causative agent and confirm delayed-type hypersensitivity. Results: We report the case of a 53-year-old woman with essential hypertension, autoimmune thyroiditis, and renal lithiasis who developed well-demarcated erythematous plaques with central vesiculation and moderate pruritus on the dorsal hand and posterior calf approximately 8 h after ingestion of a 60 mg etoricoxib tablet. Patch testing was negative, while oral challenge confirmed etoricoxib-induced FDE; celecoxib was subsequently evaluated as a potential safe alternative. Conclusions: This case underscores the importance of an integrated diagnostic approach\u2014including careful history, clinical examination, and confirmatory testing\u2014to accurately diagnose delayed cutaneous drug reactions and to identify safe therapeutic options for patients.<\/jats:p>","DOI":"10.3390\/jcm14238504","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Etoricoxib-Induced Fixed Erythema"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7255-0835","authenticated-orcid":false,"given":"Corina","family":"Porr","sequence":"first","affiliation":[{"name":"Allergology Department, Faculty of Medicine, Lucian Blaga University, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-9215","authenticated-orcid":false,"given":"Dana M.","family":"Harris","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Vidrighin","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Faculty of Medicine, Lucian Blaga University, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2806-2688","authenticated-orcid":false,"given":"Alina","family":"Catana","sequence":"additional","affiliation":[{"name":"Hematology Department, Faculty of Medicine, Lucian Blaga University, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmina","family":"Diaconu","sequence":"additional","affiliation":[{"name":"Department of Nursing and Dental Medicine, Faculty of Medicine, Lucian Blaga University, 550024 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9991-7052","authenticated-orcid":false,"given":"Emi M.","family":"Preda","sequence":"additional","affiliation":[{"name":"Department of Radiology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Radiology and Medical Imaging, \u201cFoi\u0219or\u201d Clinical Hospital of Orthopaedics, Traumatology and Osteoarticular TB, 021382 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela L.","family":"Popa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-8363","authenticated-orcid":false,"given":"Elena C.","family":"Berghea","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Clinical Allergology and Clinical Immunology, Marie S. Curie Emergency Children\u2019s Clinical Hospital, 077120 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cod.12813","article-title":"Fixed drug eruption induced by ciprofloxacin and cross-reactivity to other quinolones","volume":"77","author":"Indiveri","year":"2017","journal-title":"Contact Dermat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D3244039365","article-title":"Generalized fixed drug eruption to piperacillin\/tazobactam and review of literature","volume":"24","author":"Kornmehl","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-020-00505-3","article-title":"Fixed drug eruptions: An update, emphasizing the potentially lethal generalized bullous fixed drug eruption","volume":"21","author":"Patel","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","first-page":"e28299","article-title":"Fixed Drug Eruption: An Underrecognized Cutaneous Manifestation of a Drug Reaction in the Primary Care Setting","volume":"14","author":"Shaker","year":"2021","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-4632.2006.02853.x","article-title":"Fixed drug eruption (FDE): Changing scenario of incriminating drugs","volume":"45","author":"Sehgal","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.2001.04422.x","article-title":"Current causes of fixed drug eruption in the U.K","volume":"145","author":"Savin","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Anderson, H.J., and Lee, J.B. (2021). A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. Medicina, 57.","DOI":"10.3390\/medicina57090925"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.18176\/jiaci.0225","article-title":"Fixed Drug Eruption Due to Lorazepam","volume":"28","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hall, J.C., and Hall, B.H. (2015). Fixed drug eruptions. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy, Springer.","DOI":"10.1007\/978-1-4471-6729-7"},{"key":"ref_12","first-page":"CP15563","article-title":"Generalized Bullous Fixed Drug Eruption Induced by Chlordiazepoxide: A Case Report of a Potentially Lethal Adverse Effect","volume":"6","author":"Singh","year":"2025","journal-title":"Consort. Psychiatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000545623","article-title":"Adverse Cutaneous Reactions to Monoclonal Antibodies: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme and Fixed Drug Eruption\u2014A Systematic Review","volume":"10","author":"Kherallah","year":"2025","journal-title":"Biomed. Hub"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Baldo, B.A. (2022). Immune- and non-immunemediated adverse effects of monoclonal antibody therapy: A survey of 110 approved antibodies. Antibodies, 11.","DOI":"10.3390\/antib11010017"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Research"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chang, H.-C., Wang, T.-J., Lin, M.-H., and Chen, T.-J. (2022). A review of the systemic treatment of stevens\u2013johnson syndrome and toxic epidermal necrolysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092105"},{"key":"ref_18","first-page":"82","article-title":"Erythema multiforme: Recognition and management","volume":"100","author":"Trayes","year":"2019","journal-title":"Am. Fam. Physician."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/jamadermatol.2018.3973","article-title":"Herpes-associated erythema multiforme","volume":"155","author":"Hashemi","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00128071-200001050-00003","article-title":"Fixed drug eruptions: Incidence, recognition, and avoidance","volume":"1","author":"Lee","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_21","first-page":"e86372","article-title":"Levofloxacin-Induced Generalized Fixed Drug Eruption","volume":"17","year":"2025","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaip.2024.09.024","article-title":"Fixed drug eruption and generalized bullous fixed drug eruption: Insights from an analysis of the FDA adverse event reporting system","volume":"13","author":"Shrestha","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_23","first-page":"201","article-title":"Fixed drug eruption: A disease mediated by self-inflicted responses of intraepidermal T cells","volume":"17","author":"Shiohara","year":"2007","journal-title":"Eur. J. Dermatol. EJD"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-4362.1991.tb04354.x","article-title":"Drug-specific clinical pattern in fixed drug eruptions","volume":"30","author":"Thankappan","year":"1991","journal-title":"Int. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1346-8138.1996.tb02646.x","article-title":"Drug related involvement of specific sites in fixed eruptions: A statistical evaluation","volume":"23","author":"Sharma","year":"1996","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-4632.2006.02912.x","article-title":"Fixed drug eruption in Nigeria","volume":"45","author":"Nnoruka","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5455\/msm.2025.37.111-116","article-title":"Association Between HLA-A*02:07 and Fixed Drug Eruption Caused by Sulfamethoxazole-Trimethoprim","volume":"37","author":"Thi","year":"2025","journal-title":"Mater. Sociomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: A marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmpt-2016-0025","article-title":"An update on HLA alleles associated with adverse drug reactions","volume":"32","author":"LLerena","year":"2017","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia Pac. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B*57:01 screening and hypersensitivity reaction to abacavir between1999 and 2016 in the OPERA\u00ae observational database: A cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1097\/JW9.0000000000000231","article-title":"Generalized fixed drug eruption in skin of color","volume":"11","author":"Grewal","year":"2025","journal-title":"Int. J. Women\u2019s Dermatol."},{"key":"ref_37","first-page":"485","article-title":"Selective immediate hypersensitivity to etoricoxib","volume":"18","author":"Parra","year":"2008","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2340\/00015555-0381","article-title":"Etoricoxib-induced acute generalized exanthematous pustulosis","volume":"88","author":"Lammintausta","year":"2008","journal-title":"Acta Derm.-Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000112930","article-title":"Etoricoxib-induced erythema-multiforme-like eruption","volume":"216","author":"Thirion","year":"2008","journal-title":"Dermatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: Successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1684\/ejd.2010.0870","article-title":"Bullous fixed drug eruption to etoricoxib\u2013further evidence of intraepidermal CD8+ T cell involvement","volume":"20","author":"Duarte","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: Pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.14423\/SMJ.0000000000000195","article-title":"Fixed drug eruptions: Presentation, diagnosis, and management","volume":"107","author":"Flowers","year":"2014","journal-title":"South. Med. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11882-009-0011-8","article-title":"Fixed drug eruption: A prototypic disorder mediated by effector memory T cells","volume":"9","author":"Mizukawa","year":"2009","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_46","first-page":"33","article-title":"Generalized fixed pigmented erythema due to ARBS","volume":"105","author":"Perdomo","year":"2024","journal-title":"Rev. Argent. Dermatol."},{"key":"ref_47","unstructured":"Oakley, A., Condon, C., and Nixon, R. (2021). Fixed Drug Eruption, DermNet NZ. Available online: https:\/\/dermnetnz.org\/topics\/fixed-drug-eruption."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/cdr.cdr_79_22","article-title":"Fixed Eruptions: Drug, Food, and What More?","volume":"8","author":"Sangolli","year":"2024","journal-title":"Clin. Dermatol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.18176\/jiaci.0384","article-title":"The Lymphocyte Transformation Test Is Useful in the Diagnosis of Fixed Drug Eruption Induced by Etoricoxib","volume":"29","author":"Movsisyan","year":"2019","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaip.2019.01.032","article-title":"Bullous Fixed Drug Eruption Caused by Etoricoxib Confirmed by Patch Testing","volume":"7","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0190-9622(94)70007-9","article-title":"Genetic susceptibility to fixed drug eruption: Evidence for a link with HLA-B22","volume":"30","author":"Pellicano","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1590\/abd1806-4841.20164301","article-title":"Fixed drug eruption by etoricoxib confirmed by patch test","volume":"91","author":"Sousa","year":"2016","journal-title":"An. Bras. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Makris, M., Papapostolou, N., Koumprentziotis, I.A., Pappa, G., and Katoulis, A.C. (2024). Nimesulide-Induced Fixed Drug Eruption Followed by Etoricoxib-Induced Fixed Drug Eruption: An Unusual Case Report and Review of the Literature. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061583"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:28:49Z","timestamp":1765211329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":53,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238504"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238504","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}